Loading…
Loading…
China's Human Genetic Resources (HGR) regulatory framework rests on two layers: the 2019 State Council Administrative Regulations on Human Genetic Resources (Decree No. 717) and the 2023 NHC Implementation Rules (effective 1 July 2023) that operationalise the collection, preservation, utilisation, and cross-border transfer of genomic samples and data. The 8 May 2026 consultation draft amends the Implementation Rules in four material directions:
1. Narrowed "foreign party" definition. Current rules apply a functional "actual control" test that sweeps in VIE-structured entities and Cayman/HK-listed Chinese biotechs with significant foreign institutional ownership. The draft replaces this with a bright-line 50% equity or voting-rights threshold: Chinese biotechs with <50% foreign ownership — even if listed abroad or operated under VIE structures — will no longer be classified as "foreign parties" subject to strict HGR partner-approval and co-ownership requirements. This aligns with the broader 2026 Chinese regulatory pivot toward functional-control-over-form criteria also visible in the concurrent State Council Order 818 biomedical technologies framework.
2. Narrowed HGR Information scope. The draft restricts "HGR Information" to nucleic-acid sequence data only (genomic, transcriptomic, and epigenomic). Clinical data, imaging data, protein data, and metabolic data are explicitly excluded. Under current rules, the boundary between HGR Information and other research data is ambiguous, creating compliance friction for international clinical trials and translational research programmes. The draft resolves this by limiting the HGR-filing requirement to sequence-level data.
3. Removal of Article 37 security review. Current Article 37 mandates a separate security-review layer (beyond the standard HGR-export filing) for sensitive HGR data covering important genetic families, specific geographic regions, or large-scale sequencing datasets involving more than 500 cases. The draft eliminates this second-tier review, collapsing the dual-pathway into a single standard HGR-export filing.
4. Fast-track filing for international clinical trials. For international collaborative clinical trials that do not involve export of HGR information, the draft mandates that NHC confirm the filing on the same or next working day — replacing the existing 5-to-15-business-day standard cycle. This reduces the clock-start delay for multinational Phase II/III trial launches where China is a co-investigator jurisdiction.
The HGR draft is one component of a coordinated 2026 China life-sciences regulatory liberalisation package. The concurrent State Council Order 818 (filed 2025-09-28, effective 2026-05) restructured clinical-trial approval pathways for biomedical new technologies. Together they form the regulatory architecture enabling the NHC's stated ambition to position China as the world's largest international clinical-trial co-investigator jurisdiction by 2030.
The timing is notable: the US BIOSECURE Act (filed 2025-12-18) explicitly restricts federal contracts with companies supplying genomic-sequencing equipment or services to entities of concern (including BGI, MGI, Complete Genomics, WuXi AppTec, WuXi Biologics). The HGR draft moves in the opposite direction — relaxing the Chinese-side controls governing inbound cross-border genomic data flows from multinational research partners. The asymmetric dynamic (tightening on the US side; easing on the China side) materially shifts the compliance calculus for US-and-China-dual-headquartered life-sciences sponsors planning multi-site oncology and rare-disease trials.
structural relief from foreign-party classification removes the co-ownership and NHC-partner-approval overhead that has slowed international co-development deals.
scope (sequence data only) reduces the filing burden on translational biomarker programmes using proteomic, imaging, and metabolic endpoints.
provision benefits multinational clients co-enrolling China sites, reinforcing service-revenue growth even as the BIOSECURE Act pressure on US federal clients persists.
window and NHC's stated target to implement before the 15th FYP close (Dec 2025 goal shifted to mid-2026 in practice).
push for a restored "actual control" test on national-security grounds?
and DSL Implementing Regulations if a genomic dataset is also covered by PIPL or CSL?
data of military-service-connected populations or ethnic-minority cohorts — which were the original target of the security-review layer?